

**Supplementary Table 1. Proposed Antigen targets of interest for CAR T-cell therapy investigation in solid tumors.** The antigen targets investigated for solid tumor CAR T-cell therapy were compiled by review of the published literature. Antigens are listed in alphabetical order and the relevant citations in chronological order.

| <b>Antigen targeted</b>                                                       | <b>Tumors investigated</b>                                                                                                                                                                | <b>References</b> |
|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| <b>B7-H3</b><br><i>CD276</i>                                                  | Sarcoma and Neuroblastoma                                                                                                                                                                 | (1)               |
| <b>B7-H6</b><br><i>Nkp30</i>                                                  | Ovarian and several solid cancers                                                                                                                                                         | (2-4)             |
| <b>CAIX</b><br><i>Carbonic Anhydrase IX</i>                                   | Renal cell carcinoma                                                                                                                                                                      | (5)               |
| <b>CEA</b><br><i>Carcinoembryonic Antigen</i>                                 | Liver metastasis from Colon cancer, Colon, Pancreas, Gastric and Lung cancers                                                                                                             | (6-20)            |
| <b>CSPG4</b><br><i>Chondroitin sulfate proteoglycan-4</i>                     | Melanoma, Mesothelioma, Glioblastoma, Osteosarcoma, Breast, Head and Neck cancers                                                                                                         | (21-24)           |
| <b>DNAM-1</b><br><i>DNAX Accessory Molecule</i>                               | Melanoma                                                                                                                                                                                  | (25)              |
| <b>EpHA2</b><br><i>Ephrin type A Receptor 2</i>                               | Glioblastoma and Lung cancer                                                                                                                                                              | (26, 27)          |
| <b>EpCAM</b><br><i>Epithelial Cell Adhesion Molecule</i>                      | Prostate cancer                                                                                                                                                                           | (28, 29)          |
| <b>ERBB family</b>                                                            | Head and Neck and Breast cancers                                                                                                                                                          | (30, 31)          |
| <b>ERBB2</b>                                                                  | Prostate, Breast, Ovarian and Pancreatic cancers, Glioblastoma, Medulloblastoma, Osteosarcoma, Ewing sarcoma, Neuroectodermal tumor, Desmoplastic small round cell tumor and Fibrosarcoma | (32-48)           |
| <b>EGFRvIII</b><br><i>Epidermal Growth Factor Receptor vIII</i>               | Glioma/Glioblastoma                                                                                                                                                                       | (49-56)           |
| <b>FAP</b><br><i>Fibroblast Associated Protein</i>                            | Tumor associated fibroblast in Lung cancer, Mesothelioma, Breast and Pancreatic cancers                                                                                                   | (27, 57-59)       |
| <b>FR<math>\alpha</math> and <math>\beta</math></b><br><i>Folate Receptor</i> | Ovarian cancer                                                                                                                                                                            | (60-64)           |
| <b>GD2</b><br><i>Disialoganglioside</i>                                       | Neuroblastoma, Edwing sarcoma, Melanoma                                                                                                                                                   | (65-71)           |
| <b>GD3</b>                                                                    | Melanoma and other Neuroectodermal tumors                                                                                                                                                 | (72, 73)          |
| <b>Gp100/HLA-A2</b>                                                           | Melanoma                                                                                                                                                                                  | (74, 75)          |
| <b>GPC3</b><br><i>Glypican 3</i>                                              | Hepatocellular carcinoma                                                                                                                                                                  | (76)              |
| <b>HERK-V</b>                                                                 | Melanoma                                                                                                                                                                                  | (77)              |
| <b>MAGE-1/HLA-A1</b><br><i>Melanoma Antigen E</i>                             | Melanoma                                                                                                                                                                                  | (78, 79)          |
| <b>IL-11R<math>\alpha</math></b>                                              | Osteosarcoma                                                                                                                                                                              | (80)              |
| <b>IL-13R<math>\alpha</math>2</b>                                             | Glioma/Glioblastoma<br>Medulloblastoma                                                                                                                                                    | (81-87)           |
| <b>Lewis-Y</b>                                                                | Ovarian                                                                                                                                                                                   | (88) (89, 90)     |
| <b>LMP1</b><br><i>Latent Membrane Protein 1</i>                               | Nasopharyngeal cancer                                                                                                                                                                     | (91)              |
| <b>L1-CAM</b><br><i>CD271 L1-Cellular Adhesion Molecule</i>                   | Glioblastoma, Neuroblastoma, Ovarian, Lung and Renal carcinoma                                                                                                                            | (92, 93)          |
| <b>Muc-1</b><br><i>Mucin-1</i>                                                | Prostate and Breast cancers                                                                                                                                                               | (43, 94-96)       |
| <b>Muc-16</b><br><i>Mucin-16</i>                                              | Ovarian cancer                                                                                                                                                                            | (97, 98)          |
| <b>MSLN</b><br><i>Mesothelin</i>                                              | Ovarian, Mesothelioma, Lung cancers                                                                                                                                                       | (99-107)          |
| <b>N-cam</b><br><i>CD56 Neural cell-adhesion molecule1</i>                    | Neuroblastoma                                                                                                                                                                             | (108)             |
| <b>NKG2DL</b><br><i>NKG2D Ligands</i>                                         | Ovarian                                                                                                                                                                                   | (109, 110)        |
| <b>PSCA</b><br><i>Prostate Stem cell Antigen</i>                              | Prostate cancer                                                                                                                                                                           | (111-113)         |
| <b>PSMA</b><br><i>Prostate Specific Membrane Antigen</i>                      | Prostate                                                                                                                                                                                  | (114-117)         |
| <b>ROR1</b><br><i>Receptor tyrosine kinase-like Orphan Receptor</i>           | Epithelial solid tumors                                                                                                                                                                   | (117, 118)        |

| <b>Antigen targeted</b>                                               | <b>Tumors investigated</b>                 | <b>References</b> |
|-----------------------------------------------------------------------|--------------------------------------------|-------------------|
| <b>TAG72</b><br><i>Tumor Associated Glycoprotein 72</i>               | Gastrointestinal, Colon and Breast cancers | (119-122)         |
| <b>TRAIL R</b><br><i>Trail Receptor</i>                               | Various type of cancer                     | (123)             |
| <b>VEGFR2</b><br><i>Vascular Endothelial Growth Factor Receptor-2</i> | Tumor associated vasculature               | (124-127)         |

## Supplementary Table 2. Publications characterizing MSLN expression in solid tumors.

Following literature search, publications investigating MSLN expression by immunohistochemistry were compiled. The total number of tumors (Total #) and the number of MSLN positive tumors (MSLN+ #) were derived according to the claim from each publication. The final percentage of MSLN positivity refers to the percentage of MSLN positive tumors among the total number of tumors investigated. For further details, readers are encouraged to refer to each publication.

(128)

### (1) Esophageal cancer

| Author                  | Histological subtype                             | Total #    | MSLN+ #   | MSLN+ %                | Ref   |
|-------------------------|--------------------------------------------------|------------|-----------|------------------------|-------|
| Ordonez et al., 2003    | Esophageal adenocarcinoma and squamous carcinoma | 8          | 4         | 50                     | (128) |
| Dennis et al., 2005     | Esophageal adenocarcinoma and squamous carcinoma | 28         | 4         | 16                     | (129) |
| Alvarez et al., 2008    | Barrett associated dysplasia and adenocarcinoma  | 84         | 24        | 28                     | (130) |
| Rizk et al., 2012       | Esophageal adenocarcinoma                        | 125        | 57        | 46                     | (131) |
|                         |                                                  |            |           | <b>Range: 16-50%</b>   |       |
| <b>Calculated MSLN+</b> |                                                  | <b>245</b> | <b>89</b> | <b>Average: 35-40%</b> |       |

### (2) Breast Cancer

| Author                      | Histological subtype | Total #     | MSLN+ #    | MSLN+ %                | Ref   |
|-----------------------------|----------------------|-------------|------------|------------------------|-------|
| Ordonez et al., 2003        | Unspecified          | 12          | 0          | 0                      | (132) |
| Ordonez et al., 2003        | Unspecified          | 35          | 1          | 3                      | (128) |
| Frierson et al., 2003       | Unspecified          | 71          | 10         | 14                     | (133) |
| Dennis et al., 2005         | Unspecified          | 35          | 1          | 3                      | (129) |
| Tchou et al., 2012          | Triple negative      | 43          | 29         | 67                     | (134) |
| Tchou et al., 2012          | ER positive          | 29          | 1          | 3                      | (134) |
| Tchou et al., 2012          | HER positive         | 27          | 1          | 4                      | (134) |
| Parinyanitikul et al., 2013 | Triple negative      | 109         | 37         | 34                     | (135) |
| Wang et al., 2012           | All subtypes         | 182         | 54         | 30                     | (136) |
| Li et al., 2014             | All subtypes         | 141         | 50         | 35                     | (137) |
| Ordonez et al., 2014        | Triple negative      | 40          | 21         | 53                     | (138) |
| Ordonez et al., 2014        | Estrogen positive    | 40          | 1          | 3                      | (138) |
| Tozbikian et al., 2014      | Triple negative      | 226         | 82         | 36                     | (139) |
| Tozbikian et al., 2014      | Non Triple negative  | 88          | 14         | 16                     | (139) |
| Bayoglu et al., 2015        | Triple negative      | 71          | 30         | 42                     | (140) |
| Bayoglu et al., 2015        | HER positive         | 50          | 2          | 4                      | (140) |
|                             |                      |             |            | <b>Range: 0-67%</b>    |       |
| <b>Calculated MSLN+</b>     |                      | <b>1199</b> | <b>334</b> | <b>Average: 25-30%</b> |       |

### (3) Stomach cancer

| Author               | Total # | MSLN+ # | MSLN+ % | Ref   |
|----------------------|---------|---------|---------|-------|
| Ordonez et al., 2003 | 4       | 2       | 50      | (132) |
| Ordonez et al., 2003 | 7       | 2       | 29      | (128) |

|                         |            |            |                        |       |
|-------------------------|------------|------------|------------------------|-------|
| Dennis et al., 2005     | 34         | 7          | 21                     | (129) |
| Einama et al., 2012     | 110        | 49         | 45                     | (141) |
| Baba et al., 2012       | 212        | 124        | 58                     | (142) |
| Ito et al., 2014        | 50         | 29         | 58                     | (143) |
| <b>Range: 21-58%</b>    |            |            |                        |       |
| <b>Calculated MSLN+</b> | <b>417</b> | <b>213</b> | <b>Average: 50-55%</b> |       |

#### (4) Cholangiocarcinoma

| Author                  | Histological Subtype                    | Total #    | MSLN+ #   | MSLN+ %                | Ref   |
|-------------------------|-----------------------------------------|------------|-----------|------------------------|-------|
| Ordonez et al., 2003    | Cholangiocarcinoma and Ampulla de Vater | 22         | 10        | 45                     | (128) |
| Dennis et al., 2005     | Cholangiocarcinoma                      | 10         | 7         | 70                     | (129) |
| Hassan et al., 2005     | Common Bile Duct and Ampulla de Vater   | 21         | 20        | 95                     | (144) |
| Yu et al., 2010         | Cholangiocarcinoma                      | 9          | 3         | 33                     | (145) |
| Kawamata et al., 2012   | Extrahepatic Bile Duct cancer           | 61         | 44        | 72                     | (146) |
| Nomura et al., 2013     | Cholangiocarcinoma                      | 25         | 8         | 32                     | (147) |
| <b>Range: 32-95%</b>    |                                         |            |           |                        |       |
| <b>Calculated MSLN+</b> |                                         | <b>148</b> | <b>92</b> | <b>Average: 60-65%</b> |       |

#### (5) Pancreatic cancer

| Author                    | Histological Subtype              | Total #    | MSLN+ #    | MSLN+ %                | Ref   |
|---------------------------|-----------------------------------|------------|------------|------------------------|-------|
| Argani et al., 2001       | Pancreatic ductal adenocarcinoma  | 60         | 60         | 100                    | (148) |
| Frierson et al., 2003     | Unspecified                       | 14         | 14         | 100                    | (133) |
| Ordonez et al., 2003      | Pancreatic ductal adenocarcinoma  | 11         | 10         | 91                     | (132) |
| Ordonez et al., 2003      | Pancreatic ductal adenocarcinoma  | 14         | 12         | 86                     | (128) |
| Swierczynski et al., 2004 | Pancreatic adenocarcinoma         | 68         | 61         | 90                     | (149) |
| Hassan et al., 2005       | Pancreaticobiliary adenocarcinoma | 18         | 18         | 100                    | (144) |
| Dennis et al., 2005       | Pancreatic ductal adenocarcinoma  | 53         | 25         | 47                     | (129) |
| Inami et al., 2008        | Pancreatic ductal carcinoma       | 19         | 14         | 74                     | (150) |
| Einama et al., 2011       | Pancreatic ductal adenocarcinoma  | 66         | 57         | 86                     | (141) |
| Frank et al., 2014        | Pancreatic adenocarcinoma         | 35         | 30         | 86                     | (151) |
| Scales et al., 2014       | Pancreatic ductal adenocarcinoma  | 196        | 147        | 75                     | (152) |
| <b>Range: 47-100%</b>     |                                   |            |            |                        |       |
| <b>Calculated MSLN+</b>   |                                   | <b>554</b> | <b>448</b> | <b>Average: 80-85%</b> |       |

#### (6) Colon cancer

| Author                | Histological Subtype | Total # | MSLN+ # | MSLN+ % | Ref   |
|-----------------------|----------------------|---------|---------|---------|-------|
| Ordonez et al., 2003  | Adenocarcinoma       | 16      | 5       | 31      | (132) |
| Ordonez et al., 2003  | Adenocarcinoma       | 18      | 5       | 28      | (128) |
| Frierson et al., 2003 | Adenocarcinoma       | 56      | 17      | 30      | (133) |
| Liebig et al., 2005   | Carcinoma            | 46      | 28      | 61      | (153) |

|                         |             |            |            |                        |       |
|-------------------------|-------------|------------|------------|------------------------|-------|
| Kawamata et al., 2014   | Unspecified | 91         | 45         | 49                     | (154) |
| <b>Range: 31-61%</b>    |             |            |            |                        |       |
| <b>Calculated MSLN+</b> |             | <b>227</b> | <b>100</b> | <b>Average: 40-45%</b> |       |

### (7) Lung cancer

| Author                  | Histological Subtype         | Total #     | MSLN+ #     | MSLN+ %                | Ref        |
|-------------------------|------------------------------|-------------|-------------|------------------------|------------|
| Miettinen et al., 2003  | Lung adenocarcinoma          | 386         | 163         | 42                     | (155)      |
| Ordonez et al., 2003    | Squamous cell carcinoma      |             |             |                        |            |
| Ordonez et al., 2003    | Lung Adenocarcinoma          | 50          | 19          | 38                     | (156)      |
| Ordonez et al., 2003    | Lung Adenocarcinoma          | 34          | 14          | 41                     | (128, 138) |
| Dennis et al., 2005     | Lung Adenocarcinoma          | 53          | 19          | 36                     | (129)      |
| Ordóñez et al., 2006    | Squamous cell carcinoma      | 30          | 8           | 27                     | (157)      |
| Kushitani et al., 2007  | Lung Adenocarcinoma          | 51          | 35          | 69                     | (158)      |
| Pu et al., 2008         | Lung Adenocarcinoma          | 10          | 10          | 100                    | (159)      |
| Pu et al., 2008         | Squamous cell carcinoma      | 15          | 9           | 60                     | (159)      |
| Kachala et al., 2014    | Lung Adenocarcinoma          | 1209        | 834         | 69                     | (160)      |
| Thomas et al., 2015     | Advanced lung adenocarcinoma | 93          | 77          | 83                     | (161)      |
| <b>Range: 27-100%</b>   |                              |             |             |                        |            |
| <b>Calculated MSLN+</b> |                              | <b>1931</b> | <b>1188</b> | <b>Average: 60-65%</b> |            |

### (8) Thymic carcinoma

| Author                  | Histological Subtype | Total #   | MSLN+ #   | MSLN+ %                | Ref   |
|-------------------------|----------------------|-----------|-----------|------------------------|-------|
| Pan et al., 2003        | Thymic carcinoma     | 22        | 8         | 36                     | (162) |
| Yuanbin et al., 2014    | Thymic carcinoma     | 42        | 19        | 45                     | (163) |
| <b>Range: 36-45%</b>    |                      |           |           |                        |       |
| <b>Calculated MSLN+</b> |                      | <b>64</b> | <b>27</b> | <b>Average: 40-45%</b> |       |

### (9) Mesothelioma

| Author                 | Histological Subtype     | Total # | MSLN+ # | MSLN+ % | Ref   |
|------------------------|--------------------------|---------|---------|---------|-------|
| Ordonez et al., 2003   | Epithelioid mesothelioma | 44      | 44      | 100     | (132) |
| Ordonez et al., 2003   | Biphasic mesothelioma    | 3       | 3       | 100     | (132) |
| Ordonez et al., 2003   | Sarcomatous              | 8       | 0       | 0       | (132) |
| Ordonez et al., 2003   | Unspecified              | 60      | 60      | 100     | (156) |
| Miettinen et al., 2003 | Epithelioid mesothelioma | 28      | 25      | 89      | (155) |
| Ordonez et al., 2004   | Epithelioid mesothelioma | 40      | 40      | 100     | (164) |
| Ordonez et al., 2004   | Sarcomatoid              | 8       | 0       | 0       | (164) |
| Ordonez et al., 2006   | Epithelioid mesothelioma | 30      | 30      | 100     | (157) |
| Galloway et al., 2006  | Biphasic mesothelioma    | 8       | 8       | 100     | (165) |
| Galloway et al., 2006  | Epithelioid mesothelioma | 39      | 39      | 100     | (165) |
| Galloway et al., 2006  | Other mesothelioma       | 15      | 6       | 40      | (165) |
| Kushitani et al., 2007 | Epithelioid mesothelioma | 66      | 56      | 85      | (158) |
| Kushitani et al., 2007 | Biphasic mesothelioma    | 18      | 9       | 50      | (158) |

|                         |                          |            |            |                        |       |
|-------------------------|--------------------------|------------|------------|------------------------|-------|
| Roe et al., 2008        | Unspecified              | 47         | 36         | 77                     | (166) |
| Tan et al., 2010        | Epithelioid mesothelioma | 24         | 24         | 100                    | (167) |
| Tan et al., 2010        | Sarcomatoid              | 15         | 0          | 0                      | (167) |
| Servais et al., 2012    | Epithelioid mesothelioma | 139        | 125        | 90                     | (168) |
| Ordonez et al., 2014    | Epithelioid mesothelioma | 60         | 60         | 100                    | (138) |
| <b>Range: 0-100%</b>    |                          |            |            |                        |       |
| <b>Calculated MSLN+</b> |                          | <b>652</b> | <b>565</b> | <b>Average: 85-90%</b> |       |

#### (10) Ovarian cancer

| Author                  | Histological Subtype        | Total #    | MSLN+ #    | MSLN+ %                | Ref   |
|-------------------------|-----------------------------|------------|------------|------------------------|-------|
| Frierson et al., 2003   | Serous papillary borderline | 42         | 36         | 86                     | (133) |
| Frierson et al., 2003   | Mucinous                    | 8          | 1          | 13                     | (133) |
| Ordonez et al., 2003    | Ovarian Adenocarcinoma      | 14         | 14         | 100                    | (132) |
| Ordonez et al., 2003    | Epithelial ovarian cancer   | 40         | 35         | 88                     | (128) |
| Drapkin et al., 2004    | Papillary serous            | 16         | 12         | 75                     | (169) |
| Dennis et al., 2005     | Serous adenocarcinoma       | 18         | 17         | 94                     | (129) |
| Dennis et al., 2005     | Mucinous adenocarcinoma     | 10         | 3          | 30                     | (129) |
| Rosen et al., 2005      | Epithelial Ovarian cancer   | 60         | 20         | 33                     | (170) |
| Hassan et al., 2005     | Epithelial Ovarian cancer   | 48         | 34         | 71                     | (171) |
| Cao et al., 2005        | Primary Mucinous            | 35         | 6          | 17                     | (172) |
| Yen et al., 2006        | Serous carcinoma            | 198        | 110        | 56                     | (173) |
| Scales et al., 2014     | Unspecified adenocarcinomas | 86         | 73         | 85                     | (152) |
| Scales et al., 2014     | Serous adenocarcinoma       | 43         | 42         | 98                     | (152) |
| Scales et al., 2014     | Mucinous ovarian tumor      | 10         | 1          | 10                     | (152) |
| Scales et al., 2014     | Clear cell                  | 13         | 5          | 38                     | (152) |
| <b>Range 10-100%</b>    |                             |            |            |                        |       |
| <b>Calculated MSLN+</b> |                             | <b>641</b> | <b>409</b> | <b>Average: 60-65%</b> |       |

#### (11) Endometrial cancer

| Author                  | Total # | MSLN+ #    | MSLN+ %    | Ref                    |  |
|-------------------------|---------|------------|------------|------------------------|--|
| Frierson et al., 2003   | 22      | 13         | 59         | (133)                  |  |
| Ordonez et al., 2003    | 6       | 4          | 67         | (132)                  |  |
| Ordonez et al., 2003    | 11      | 7          | 64         | (128)                  |  |
| Dennis et al., 2005     | 10      | 5          | 50         | (129)                  |  |
| Dainty et al., 2007     | 360     | 66         | 18         | (174)                  |  |
| Obulhasim et al., 2010  | 16      | 8          | 50         | (175)                  |  |
| <b>Range: 18-67%</b>    |         |            |            |                        |  |
| <b>Calculated MSLN+</b> |         | <b>425</b> | <b>103</b> | <b>Average: 20-25%</b> |  |

**Supplementary Table 3. Incidence estimated for patients with solid tumors expressing MSLN.**

| <b>Cancer Subtype</b>            | <b>Annual cancer incidence in US (2014)</b> | <b>MSLN expression (%)</b> | <b>Estimated number of MSLN+ patients</b> |
|----------------------------------|---------------------------------------------|----------------------------|-------------------------------------------|
| Esophageal Adenocarcinoma        | 9,085 (NCI)                                 | 37                         | 3,361                                     |
| Breast Cancer                    | 232,670 (SEER)                              | 28                         | 65,148                                    |
| Stomach Cancer                   | 22,220 (SEER)                               | 51                         | 11,332                                    |
| Cholangiocarcinoma               | 2,500 (NCI)                                 | 62                         | 1,550                                     |
| Pancreatic Ductal Adenocarcinoma | 41,778 (NCI)                                | 81                         | 33,840                                    |
| Colon Cancer                     | 136,830 (NCI)                               | 44                         | 60,205                                    |
| Lung Cancer                      | 224,210 (NCI)                               | 62                         | 139,010                                   |
| Thymic carcinoma                 | 1,000 (NCI)                                 | 42                         | 420                                       |
| Mesothelioma                     | 2,500 (NCI)                                 | 86                         | 2,150                                     |
| Ovarian Cancer                   | 21,980 (SEER)                               | 64                         | 14,067                                    |
| Endometrial Cancer               | 52,630 (SEER)                               | 24                         | 12,631                                    |
| <b>Total of patients</b>         | <b>747,403</b>                              | <b>46%</b>                 | <b>343,714</b>                            |

Cancer subtype incidence obtained from NCI and SEER database.

**Supplementary Table 4. Prevalence estimated for patients with solid tumors expressing MSLN.**

Cancer subtype prevalence obtained from NCI and SEER database.

| <b>Cancer Subtype</b>            | <b>Annual cancer prevalence in US (2011)</b> | <b>MSLN expression (%)</b> | <b>Estimated number of MSLN+ patients</b> |
|----------------------------------|----------------------------------------------|----------------------------|-------------------------------------------|
| Esophageal Adenocarcinoma        | 24,148 (SEER)                                | 37                         | 8,935                                     |
| Breast Cancer                    | 2,899,726 (SEER)                             | 28                         | 811,923                                   |
| Stomach Cancer                   | 74,035 (SEER)                                | 51                         | 37,758                                    |
| Cholangiocarcinoma               | 4,861 (NCI)                                  | 62                         | 3,013                                     |
| Pancreatic Ductal Adenocarcinoma | 39,184 (SEER)                                | 81                         | 31,739                                    |
| Colon Cancer                     | 1,162,426 (SEER)                             | 44                         | 511,467                                   |
| Lung Cancer                      | 402,326 (SEER)                               | 62                         | 249,442                                   |
| Thymic carcinoma                 | 957 (NCI)                                    | 42                         | 402                                       |
| Mesothelioma                     | 5,735 (NCI)                                  | 86                         | 4,932                                     |
| Ovarian Cancer                   | 188,867 (SEER)                               | 64                         | 120,875                                   |
| Endometrial Cancer               | 610,804 (SEER)                               | 24                         | 146,593                                   |
| <b>Total of patients</b>         | <b>5,413,069</b>                             | <b>36%</b>                 | <b>1,927,079</b>                          |



## Supplementary References:

1. Cheung NK, Guo HF, Modak S, Cheung IY. Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy. *Hybrid Hybridomics*. 2003;22:209-18.
2. Zhang T, Wu MR, Sentman CL. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. *J Immunol*. 2012;189:2290-9.
3. Wu MR, Zhang T, DeMars LR, Sentman CL. B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity. *Gene Ther*. 2015:[Epub ahead of print].
4. Wu MR, Zhang T, Gacerez AT, Coupet TA, DeMars LR, Sentman CL. B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity. *J Immunol*. 2015;194:5305-11.
5. Lamers CH, Sleijfer S, van Steenberghe S, van Elzakker P, van Krimpen B, Groot C, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. *Mol Ther*. 2013;21:904-12.
6. Darcy PK, Kershaw MH, Trapani JA, Smyth MJ. Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma. *Eur J Immunol*. 1998;28:1663-72.
7. Nolan KF, Yun CO, Akamatsu Y, Murphy JC, Leung SO, Beecham EJ, et al. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. *Clin Cancer Res*. 1999;5:3928-41.
8. Darcy PK, Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM, et al. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. *J Immunol*. 2000;164:3705-12.
9. Hombach A, Koch D, Sircar R, Heuser C, Diehl V, Kruis W, et al. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. *Gene Ther*. 1999;6:300-4.
10. Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM, Smyth MJ, et al. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. *J Immunol*. 2001;166:182-7.
11. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, et al. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. *J Immunol*. 2002;169:5780-6.
12. Schirmann T, Pecher G. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo. *Cancer Gene Ther*. 2002;9:390-8.
13. Arakawa F, Shibaguchi H, Xu Z, Kuroki M. Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity. *Anticancer Res*. 2002;22:4285-9.
14. Gyobu H, Tsuji T, Suzuki Y, Ohkuri T, Chamoto K, Kuroki M, et al. Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor. *Cancer Res*. 2004;64:1490-5.
15. Shibaguchi H, Luo NX, Kuroki M, Zhao J, Huang J, Hachimine K, et al. A fully human chimeric immune receptor for retargeting T-cells to CEA-expressing tumor cells. *Anticancer Res*. 2006;26:4067-72.
16. Emtage PC, Lo AS, Gomes EM, Liu DL, Gonzalo-Daganzo RM, Junghans RP. Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation. *Clin Cancer Res*. 2008;14:8112-22.
17. Chmielewski M, Hahn O, Rapp G, Nowak M, Schmidt-Wolf IH, Hombach AA, et al. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. *Gastroenterology*. 2012;143:1095-107 e2.
18. Chmielewski M, Rapp G, Hombach AA, Abken H. T cells redirected by a CD3zeta chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term. *Gene Ther*. 2013;20:177-86.
19. Burga RA, Thorn M, Point GR, Guha P, Nguyen CT, Licata LA, et al. Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. *Cancer Immunol Immunother*. 2015;64:817-29.
20. Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR, et al. Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases. *Clin Cancer Res*. 2015;21:3149-59.

21. Beard RE, Zheng Z, Lagisetty KH, Burns WR, Tran E, Hewitt SM, et al. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells. *J Immunother Cancer*. 2014;2:25.
22. Burns WR, Zhao Y, Frankel TL, Hinrichs CS, Zheng Z, Xu H, et al. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. *Cancer Res*. 2010;70:3027-33.
23. Geldres C, Savoldo B, Hoyos V, Caruana I, Zhang M, Yvon E, et al. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. *Clin Cancer Res*. 2014;20:962-71.
24. Schmidt P, Kopecky C, Hombach A, Zigrino P, Mauch C, Abken H. Eradication of melanomas by targeted elimination of a minor subset of tumor cells. *Proc Natl Acad Sci U S A*. 2011;108:2474-9.
25. Wu MR, Zhang T, Alcon A, Sentman CL. DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma. *Cancer Immunol Immunother*. 2015;64:409-18.
26. Chow KK, Naik S, Kakarla S, Brawley VS, Shaffer DR, Yi Z, et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. *Mol Ther*. 2013;21:629-37.
27. Kakarla S, Chow KK, Mata M, Shaffer DR, Song XT, Wu MF, et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. *Mol Ther*. 2013;21:1611-20.
28. Shirasu N, Yamada H, Shibaguchi H, Kuroki M, Kuroki M. Molecular characterization of a fully human chimeric T-cell antigen receptor for tumor-associated antigen EpCAM. *J Biomed Biotechnol*. 2012;2012:853879.
29. Deng Z, Wu Y, Ma W, Zhang S, Zhang YQ. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. *BMC Immunol*. 2015;16:1.
30. Davies DM, Foster J, Van Der Stegen SJ, Parente-Pereira AC, Chiapero-Stanke L, Delinassios GJ, et al. Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. *Mol Med*. 2012;18:565-76.
31. Papa S, van Schalkwyk M, Maher J. Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors. *Methods Mol Biol*. 2015;1317:365-82.
32. Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. *J Immunol*. 1993;151:6577-82.
33. Moritz D, Wels W, Mattern J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. *Proc Natl Acad Sci U S A*. 1994;91:4318-22.
34. Haynes NM, Smyth MJ, Kershaw MH, Trapani JA, Darcy PK. Fas-ligand-mediated lysis of erbB-2-expressing tumour cells by redirected cytotoxic T lymphocytes. *Cancer Immunol Immunother*. 1999;47:278-86.
35. Pinthus JH, Waks T, Kaufman-Francis K, Schindler DG, Harmelin A, Kanety H, et al. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. *Cancer Res*. 2003;63:2470-6.
36. Ahmed N, Ratnayake M, Savoldo B, Perlaky L, Dotti G, Wels WS, et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. *Cancer Res*. 2007;67:5957-64.
37. Li S, Yang J, Urban FA, MacGregor JN, Hughes DP, Chang AE, et al. Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigen-specific tumor regression. *Cancer Gene Ther*. 2008;15:382-92.
38. Wang H, Wei H, Zhang R, Hou S, Li B, Qian W, et al. Genetically targeted T cells eradicate established breast cancer in syngeneic mice. *Clin Cancer Res*. 2009;15:943-50.
39. Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. *Mol Ther*. 2009;17:1779-87.
40. Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. *J Immunol*. 2009;183:5563-74.
41. Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. *Clin Cancer Res*. 2010;16:474-85.
42. Duong CP, Westwood JA, Berry LJ, Darcy PK, Kershaw MH. Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. *Immunotherapy*. 2011;3:33-48.
43. Wilkie S, van Schalkwyk MC, Hobbs S, Davies DM, van der Stegen SJ, Pereira AC, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. *J Clin Immunol*. 2012;32:1059-70.
44. Lanitis E, Dangaj D, Hagemann IS, Song DG, Best A, Sandaltzopoulos R, et al. Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. *PLoS One*. 2012;7:e49829.

45. Maliar A, Servais C, Waks T, Chmielewski M, Lavy R, Altevogt P, et al. Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. *Gastroenterology*. 2012;143:1375-84 e1-5.
46. Rainusso N, Brawley VS, Ghazi A, Hicks MJ, Gottschalk S, Rosen JM, et al. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. *Cancer Gene Ther*. 2012;19:212-7.
47. Sun M, Shi H, Liu C, Liu J, Liu X, Sun Y. Construction and evaluation of a novel humanized HER2-specific chimeric receptor. *Breast Cancer Res*. 2014;16:R61.
48. Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human Epidermal Growth Factor Receptor 2 (HER2)-Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. *J Clin Oncol*. 2015;33:1688-96.
49. Ohno M, Natsume A, Ichiro Iwami K, Iwamizu H, Noritake K, Ito D, et al. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen. *Cancer Sci*. 2010;101:2518-24.
50. Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. *Hum Gene Ther*. 2012;23:1043-53.
51. Choi BD, Suryadevara CM, Gedeon PC, Herndon JE, 2nd, Sanchez-Perez L, Bigner DD, et al. Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. *J Clin Neurosci*. 2014;21:189-90.
52. Ohno M, Ohkuri T, Kosaka A, Tanahashi K, June CH, Natsume A, et al. Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. *J Immunother Cancer*. 2013;1:21.
53. Shen CJ, Yang YX, Han EQ, Cao N, Wang YF, Wang Y, et al. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. *J Hematol Oncol*. 2013;6:33.
54. Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. *Clin Cancer Res*. 2014;20:972-84.
55. Miao H, Choi BD, Suryadevara CM, Sanchez-Perez L, Yang S, De Leon G, et al. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. *PLoS One*. 2014;9:e94281.
56. Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. *Sci Transl Med*. 2015;7:275ra22.
57. Petrusch U, Schuberth PC, Hagedorn C, Soltermann A, Tomaszek S, Stahel R, et al. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). *BMC Cancer*. 2012;12:615.
58. Schuberth PC, Hagedorn C, Jensen SM, Gulati P, van den Broek M, Mischo A, et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. *J Transl Med*. 2013;11:187.
59. Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. *Cancer Immunol Res*. 2014;2:154-66.
60. Parker LL, Do MT, Westwood JA, Wunderlich JR, Dudley ME, Rosenberg SA, et al. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. *Hum Gene Ther*. 2000;11:2377-87.
61. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. *Clin Cancer Res*. 2006;12:6106-15.
62. Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). *Cancer Res*. 2011;71:4617-27.
63. Kandalafi LE, Powell DJ, Jr., Coukos G. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. *J Transl Med*. 2012;10:157.
64. Song DG, Ye Q, Poussin M, Liu L, Figini M, Powell DJ, Jr. A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity. *Oncotarget*. 2015.

65. Krause A, Guo HF, Latouche JB, Tan C, Cheung NK, Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. *J Exp Med.* 1998;188:619-26.
66. Rossig C, Bollard CM, Nuchtern JG, Merchant DA, Brenner MK. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. *Int J Cancer.* 2001;94:228-36.
67. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. *Nat Med.* 2008;14:1264-70.
68. Yvon E, Del Vecchio M, Savoldo B, Hoyos V, Dutour A, Anichini A, et al. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. *Clin Cancer Res.* 2009;15:5852-60.
69. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. *Blood.* 2011;118:6050-6.
70. Kailayangiri S, Altvater B, Meltzer J, Pscherer S, Luecke A, Dierkes C, et al. The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. *Br J Cancer.* 2012;106:1123-33.
71. Singh N, Liu X, Hulitt J, Jiang S, June CH, Grupp SA, et al. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. *Cancer Immunol Res.* 2014;2:1059-70.
72. Yun CO, Nolan KF, Beecham EJ, Reisfeld RA, Junghans RP. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. *Neoplasia.* 2000;2:449-59.
73. Lo AS, Ma Q, Liu DL, Junghans RP. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. *Clin Cancer Res.* 2010;16:2769-80.
74. Zhang G, Liu R, Zhu X, Wang L, Ma J, Han H, et al. Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody. *Immunol Cell Biol.* 2013;91:615-24.
75. Zhang G, Wang L, Cui H, Wang X, Zhang G, Ma J, et al. Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. *Sci Rep.* 2014;4:3571.
76. Gao H, Li K, Tu H, Pan X, Jiang H, Shi B, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. *Clin Cancer Res.* 2014;20:6418-28.
77. Krishnamurthy J, Rabinovich BA, Mi T, Switzer KC, Olivares S, Maiti SN, et al. Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma. *Clin Cancer Res.* 2015;21:3241-51.
78. Willemsen RA, Debets R, Hart E, Hoogenboom HR, Bolhuis RL, Chames P. A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes. *Gene Ther.* 2001;8:1601-8.
79. Willemsen RA, Ronteltap C, Chames P, Debets R, Bolhuis RL. T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. *J Immunol.* 2005;174:7853-8.
80. Huang G, Yu L, Cooper LJ, Hollomon M, Huls H, Kleinerman ES. Genetically modified T cells targeting interleukin-11 receptor alpha-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. *Cancer Res.* 2012;72:271-81.
81. Stastny MJ, Brown CE, Ruel C, Jensen MC. Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells. *J Pediatr Hematol Oncol.* 2007;29:669-77.
82. Chang L, Chang WC, McNamara G, Aguilar B, Ostberg JR, Jensen MC. Transgene-enforced co-stimulation of CD4+ T cells leads to enhanced and sustained anti-tumor effector functioning. *Cytotherapy.* 2007;9:771-84.
83. Lazovic J, Jensen MC, Ferkassian E, Aguilar B, Raubitschek A, Jacobs RE. Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme. *Clin Cancer Res.* 2008;14:3832-9.
84. Kong S, Sengupta S, Tyler B, Bais AJ, Ma Q, Doucette S, et al. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. *Clin Cancer Res.* 2012;18:5949-60.
85. Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. *Mol Ther.* 2013;21:2087-101.
86. Krebs S, Chow KK, Yi Z, Rodriguez-Cruz T, Hegde M, Gerken C, et al. T cells redirected to interleukin-13Ralpha2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Ralpha1. *Cytotherapy.* 2014;16:1121-31.

87. Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC, et al. Bioactivity and Safety of IL13Alpha2-Redirected Chimeric Antigen Receptor CD8+ T cells in Patients with Recurrent Glioblastoma. *Clin Cancer Res.* 2015.
88. Westwood JA, Smyth MJ, Teng MW, Moeller M, Trapani JA, Scott AM, et al. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. *Proc Natl Acad Sci U S A.* 2005;102:19051-6.
89. Westwood JA, Murray WK, Trivett M, Haynes NM, Solomon B, Mileskin L, et al. The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum. *J Immunother.* 2009;32:292-301.
90. Neeson P, Shin A, Tainton KM, Guru P, Prince HM, Harrison SJ, et al. Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype. *Gene Ther.* 2010;17:1105-16.
91. Tang X, Zhou Y, Li W, Tang Q, Chen R, Zhu J, et al. T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo. *J Biomed Res.* 2014;28:468-75.
92. Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. *Mol Ther.* 2007;15:825-33.
93. Hong H, Stastny M, Brown C, Chang WC, Ostberg JR, Forman SJ, et al. Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes. *J Immunother.* 2014;37:93-104.
94. Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. *J Immunol.* 2008;180:4901-9.
95. Bakhtiari SH, Rahbarizadeh F, Hasannia S, Ahmadvand D, Iri-Sofla FJ, Rasaei MJ. Anti-MUC1 nanobody can redirect T-body cytotoxic effector function. *Hybridoma (Larchmt).* 2009;28:85-92.
96. Sanchez C, Chan R, Bajgain P, Rambally S, Palapattu G, Mims M, et al. Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. *Prostate Cancer Prostatic Dis.* 2013;16:123-31, S1.
97. Chekmasova AA, Brentjens RJ. Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer. *Discov Med.* 2010;9:62-70.
98. Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors. *Oncoimmunology.* 2015;4:e994446.
99. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhali M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. *Proc Natl Acad Sci U S A.* 2009;106:3360-5.
100. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. *Cancer Res.* 2010;70:9053-61.
101. Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, et al. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. *Mol Ther.* 2012;20:633-43.
102. Riese MJ, Wang LC, Moon EK, Joshi RP, Ranganathan A, June CH, et al. Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. *Cancer Res.* 2013;73:3566-77.
103. Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. *Clin Cancer Res.* 2014;20:4262-73.
104. Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, et al. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. *Blood.* 2014;124:1070-80.
105. Beatty GL. Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma. *Oncoimmunology.* 2014;3:e28327.
106. Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. *Sci Transl Med.* 2014;6:261ra151.
107. Wang E, Wang LC, Tsai CY, Bhoj V, Gershenson Z, Moon E, et al. Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors. *Cancer Immunol Res.* 2015;3:815-26.

108. Gilham DE, O'Neil A, Hughes C, Guest RD, Kirillova N, Lehane M, et al. Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors. *J Immunother.* 2002;25:139-51.
109. Barber A, Rynda A, Sentman CL. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. *J Immunol.* 2009;183:6939-47.
110. Song DG, Ye Q, Santoro S, Fang C, Best A, Powell DJ, Jr. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition. *Hum Gene Ther.* 2013;24:295-305.
111. Morgenroth A, Cartellieri M, Schmitz M, Gunes S, Weigle B, Bachmann M, et al. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. *Prostate.* 2007;67:1121-31.
112. Hillerdal V, Ramachandran M, Leja J, Essand M. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice. *BMC Cancer.* 2014;14:30.
113. Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, et al. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. *Hum Gene Ther.* 2014;25:1003-12.
114. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. *Nat Biotechnol.* 2002;20:70-5.
115. Ma Q, Safar M, Holmes E, Wang Y, Boynton AL, Junghans RP. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. *Prostate.* 2004;61:12-25.
116. Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. *Cancer Res.* 2005;65:9080-8.
117. Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. *Clin Cancer Res.* 2013;19:3153-64.
118. Deniger DC, Yu J, Huls MH, Figliola MJ, Mi T, Maiti SN, et al. Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations. *PLoS One.* 2015;10:e0128151.
119. Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Kruis W, et al. T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. *Gastroenterology.* 1997;113:1163-70.
120. McGuinness RP, Ge Y, Patel SD, Kashmiri SV, Lee HS, Hand PH, et al. Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. *Hum Gene Ther.* 1999;10:165-73.
121. Patel SD, Moskalenko M, Tian T, Smith D, McGuinness R, Chen L, et al. T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors. *Cancer Gene Ther.* 2000;7:1127-34.
122. Sharifzadeh Z, Rahbarizadeh F, Shokrgozar MA, Ahmadvand D, Mahboudi F, Jamnani FR, et al. Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents. *Cancer Lett.* 2013;334:237-44.
123. Kobayashi E, Kishi H, Ozawa T, Hamana H, Nakagawa H, Jin A, et al. A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells. *Biochem Biophys Res Commun.* 2014;453:798-803.
124. Chinnasamy D, Yu Z, Kerkar SP, Zhang L, Morgan RA, Restifo NP, et al. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. *Clin Cancer Res.* 2012;18:1672-83.
125. Kanagawa N, Yanagawa T, Nakagawa T, Okada N, Nakagawa S. Tumor vessel-injuring ability improves antitumor effect of cytotoxic T lymphocytes in adoptive immunotherapy. *Cancer Gene Ther.* 2013;20:57-64.
126. Chinnasamy D, Tran E, Yu Z, Morgan RA, Restifo NP, Rosenberg SA. Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. *Cancer Res.* 2013;73:3371-80.
127. Wang W, Ma Y, Li J, Shi HS, Wang LQ, Guo FC, et al. Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency. *Gene Ther.* 2013;20:970-8.
128. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. *Am J Surg Pathol.* 2003;27:1418-28.
129. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. *Clin Cancer Res.* 2005;11:3766-72.

130. Alvarez H, Rojas PL, Yong KT, Ding H, Xu G, Prasad PN, et al. Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy. *Nanomedicine*. 2008;4:295-301.
131. Rizk NP, Servais EL, Tang LH, Sima CS, Gerdes H, Fleisher M, et al. Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma. *Cancer Epidemiol Biomarkers Prev*. 2012;21:482-6.
132. Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. *Mod Pathol*. 2003;16:192-7.
133. Frierson HF, Jr., Moskaluk CA, Powell SM, Zhang H, Cerilli LA, Stoler MH, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. *Hum Pathol*. 2003;34:605-9.
134. Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, et al. Mesothelin, a novel immunotherapy target for triple negative breast cancer. *Breast Cancer Res Treat*. 2012;133:799-804.
135. Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez-Macgregor M, Smart M, et al. Mesothelin expression and survival outcomes in triple receptor negative breast cancer. *Clin Breast Cancer*. 2013;13:378-84.
136. Wang L, Niu Z, Zhang L, Liu X, Wang X, Li F, et al. Clinicopathological significance of mesothelin expression in invasive breast cancer. *J Int Med Res*. 2012;40:909-16.
137. Li YR, Xian RR, Ziober A, Conejo-Garcia J, Perales-Puchalt A, June CH, et al. Mesothelin expression is associated with poor outcomes in breast cancer. *Breast Cancer Res Treat*. 2014;147:675-84.
138. Ordonez NG, Sahin AA. Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study. *Hum Pathol*. 2014;45:1529-40.
139. Tozbikian G, Brogi E, Kadota K, Catalano J, Akram M, Patil S, et al. Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. *PLoS One*. 2014;9:e114900.
140. Bayoglu IV, Kucukzeybek BB, Kucukzeybek Y, Varol U, Yildiz I, Alacacioglu A, et al. Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers. *Biomed Pharmacother*. 2015;70:190-5.
141. Einama T, Homma S, Kamachi H, Kawamata F, Takahashi K, Takahashi N, et al. Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. *Br J Cancer*. 2012;107:137-42.
142. Baba K, Ishigami S, Arigami T, Uenosono Y, Okumura H, Matsumoto M, et al. Mesothelin expression correlates with prolonged patient survival in gastric cancer. *J Surg Oncol*. 2012;105:195-9.
143. Ito T, Kajino K, Abe M, Sato K, Maekawa H, Sakurada M, et al. ERC/mesothelin is expressed in human gastric cancer tissues and cell lines. *Oncol Rep*. 2014;31:27-33.
144. Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. *Am J Clin Pathol*. 2005;124:838-45.
145. Yu L, Feng M, Kim H, Phung Y, Kleiner DE, Gores GJ, et al. Mesothelin as a potential therapeutic target in human cholangiocarcinoma. *J Cancer*. 2010;1:141-9.
146. Kawamata F, Kamachi H, Einama T, Homma S, Tahara M, Miyazaki M, et al. Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer. *Int J Oncol*. 2012;41:2109-18.
147. Nomura R, Fujii H, Abe M, Sugo H, Ishizaki Y, Kawasaki S, et al. Mesothelin expression is a prognostic factor in cholangiocellular carcinoma. *Int Surg*. 2013;98:164-9.
148. Argani Pedram I-DC, Byungwoo Ryu, et al. Mesothelin Is Overexpressed in the Vast Majority of Ductal Adenocarcinomas of the Pancreas: Identification of a New Pancreatic Cancer Marker by Serial Analysis of Gene Expression (SAGE). *Clin Cancer Res*. 2001;7:3862-8.
149. Swierczynski SL, Maitra A, Abraham SC, Iacobuzio-Donahue CA, Ashfaq R, Cameron JL, et al. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. *Hum Pathol*. 2004;35:357-66.
150. Inami K, Kajino K, Abe M, Hagiwara Y, Maeda M, Suyama M, et al. Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. *Oncol Rep*. 2008;20:1375-80.
151. Frank R, Li S, Ahmad NA, Sepulveda AR, Jhala NC. Mesothelin expression in pancreatic mucinous cysts. *Am J Clin Pathol*. 2014;142:313-9.
152. Scales SJ, Gupta N, Pacheco G, Firestein R, French DM, Koeppen H, et al. An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models. *Mol Cancer Ther*. 2014;13:2630-40.

153. Liebig B, Brabletz T, Staeger MS, Wulfanger J, Riemann D, Burdach S, et al. Forced expression of deltaN-TCF-1B in colon cancer derived cell lines is accompanied by the induction of CEACAM5/6 and mesothelin. *Cancer Lett.* 2005;223:159-67.
154. Kawamata F, Homma S, Kamachi H, Einama T, Kato Y, Tsuda M, et al. C-ERC/mesothelin provokes lymphatic invasion of colorectal adenocarcinoma. *J Gastroenterol.* 2014;49:81-92.
155. Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. *Am J Surg Pathol.* 2003;27:150-8.
156. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. *Am J Surg Pathol.* 2003;27:1031-51.
157. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. *Mod Pathol.* 2006;19:417-28.
158. Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, Inai K. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. *Pathol Int.* 2007;57:190-9.
159. Pu RT, Pang Y, Michael CW. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. *Diagn Cytopathol.* 2008;36:20-5.
160. Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K, et al. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. *Clin Cancer Res.* 2014;20:1020-8.
161. Anish Thomas YC, Seth m. Steinberg, Ji Luo, Svetlana Paek, Mark Raffeld, Zied Abdullaev, Chritine Alewine, Arun Rajan, Giuseppe giaccone, Ira Pastan, Markku Miettinen, Raffit Hassan High Mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and poor prognosis *Oncotarget.* 2015.
162. Pan CC, Chen PC, Chou TY, Chiang H. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma. *Hum Pathol.* 2003;34:1155-62.
163. Yuanbin Chen AT, Arlene W Berman, Markku Miettinen, Raffit Hassan, Arun Rajan. Mesothelin expression in thymic epithelial tumors (TETs). 2014 ASCO Annual Meeting; 2014.
164. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. *Hum Pathol.* 2004;35:697-710.
165. Galloway ML, Murray D, Moffat DF. The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies. *Histopathology.* 2006;48:767-9.
166. Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, et al. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. *Lung Cancer.* 2008;61:235-43.
167. Tan K, Kajino K, Momose S, Masaoka A, Sasahara K, Shiomi K, et al. Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter. *Hum Pathol.* 2010;41:1330-8.
168. Servais EL, Colovos C, Rodriguez L, Bograd AJ, Nitadori J, Sima C, et al. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. *Clin Cancer Res.* 2012;18:2478-89.
169. Drapkin R, Crum CP, Hecht JL. Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia. *Hum Pathol.* 2004;35:1014-21.
170. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. *Gynecol Oncol.* 2005;99:267-77.
171. Hassan R, Kreitman RJ, Pastan I, Willingham MC. Localization of mesothelin in epithelial ovarian cancer. *Appl Immunohistochem Mol Morphol.* 2005;13:243-7.
172. Cao D, Ji H, Ronnett BM. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. *Int J Gynecol Pathol.* 2005;24:67-72.
173. Yen MJ, Hsu CY, Mao TL, Wu TC, Roden R, Wang TL, et al. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. *Clin Cancer Res.* 2006;12:827-31.
174. Dainty LA, Risinger JI, Morrison C, Chandramouli GV, Bidus MA, Zahn C, et al. Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma. *Gynecol Oncol.* 2007;105:563-70.
175. Obulhasim G, Fujii H, Matsumoto T, Yasen M, Abe M, Matsuoka S, et al. Mesothelin gene expression and promoter methylation/hypomethylation in gynecological tumors. *Eur J Gynaecol Oncol.* 2010;31:63-71.